Paclitaxel-eluting resorbable scaffold - 480 Biomedical

Drug Profile

Paclitaxel-eluting resorbable scaffold - 480 Biomedical

Alternative Names: Paclitaxel-eluting stent - 480 Biomedical; Stanza DRS; Stanza Drug-eluting Resorbable Scaffold

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 480 Biomedical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral arterial disorders

Most Recent Events

  • 01 Aug 2016 Paclitaxel-eluting resorbable scaffold is still in phase III trials for Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082)
  • 31 Oct 2013 Phase-III clinical trials in Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082) (EudraCT2013-002467-26)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top